TY - CHAP
T1 - Flow cytometry-assisted analysis of phenotypic maturation markers on an immortalized dendritic cell line
AU - Campia, Ginevra
AU - Beltrán-Visiedo, Manuel
AU - Soler-Agesta, Ruth
AU - Sato, Ai
AU - Bloy, Norma
AU - Zhao, Liwei
AU - Liu, Peng
AU - Kepp, Oliver
AU - Kroemer, Guido
AU - Galluzzi, Lorenzo
AU - Galassi, Claudia
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Dendritic cells (DCs), and especially so conventional type I DCs (cDC1s), are fundamental regulators of anticancer immunity, largely reflecting their superior ability to engulf tumor-derived material and process it for cross-presentation on MHC Class I molecules to CD8+ cytotoxic T lymphocytes (CTLs). Thus, investigating key DC functions including (but not limited to) phagocytic capacity, expression of CTL-activating ligands on the cell surface, and cross-presentation efficacy is an important component of multiple immuno-oncology studies. Unfortunately, DCs are terminally differentiated cells, implying that they cannot be propagated indefinitely in vitro and hence must be generated ad hoc from circulating or bone marrow-derived precursors, which presents several limitations. Here, we propose a simple, cytofluorometric method to quantify phenotypic activation markers including CD80, CD86 and MHC class II molecules on the surface of a conditionally immortalized immature DC line that can be indefinitely propagated in vitro but also driven into maturation at will with a simple change in culture conditions. Upon appropriate scaling and automatization, this approach is compatible with high-throughput screening programs for the discovery of novel DC activators that do not suffer from batch variability and other limitations associated with the generation of fresh DCs.
AB - Dendritic cells (DCs), and especially so conventional type I DCs (cDC1s), are fundamental regulators of anticancer immunity, largely reflecting their superior ability to engulf tumor-derived material and process it for cross-presentation on MHC Class I molecules to CD8+ cytotoxic T lymphocytes (CTLs). Thus, investigating key DC functions including (but not limited to) phagocytic capacity, expression of CTL-activating ligands on the cell surface, and cross-presentation efficacy is an important component of multiple immuno-oncology studies. Unfortunately, DCs are terminally differentiated cells, implying that they cannot be propagated indefinitely in vitro and hence must be generated ad hoc from circulating or bone marrow-derived precursors, which presents several limitations. Here, we propose a simple, cytofluorometric method to quantify phenotypic activation markers including CD80, CD86 and MHC class II molecules on the surface of a conditionally immortalized immature DC line that can be indefinitely propagated in vitro but also driven into maturation at will with a simple change in culture conditions. Upon appropriate scaling and automatization, this approach is compatible with high-throughput screening programs for the discovery of novel DC activators that do not suffer from batch variability and other limitations associated with the generation of fresh DCs.
KW - BCL2
KW - Immune checkpoint inhibitors
KW - TLR agonists
KW - Type I interferon
KW - Venetoclax
KW - mtDNA
UR - http://www.scopus.com/inward/record.url?scp=85195868321&partnerID=8YFLogxK
U2 - 10.1016/bs.mcb.2024.05.008
DO - 10.1016/bs.mcb.2024.05.008
M3 - Chapter
AN - SCOPUS:85195868321
SN - 9780443296222
T3 - Methods in Cell Biology
SP - 153
EP - 168
BT - Immuno-oncology and immunotherapy - Part A
PB - Academic Press Inc.
ER -